In a single-arm phase 2 trial, Jian Zhang, Yanchun Meng &co assess activity & safety of combining dalpiciclib with pyrotinib & endocrine therapy in patients receiving first- or second-line treatment for ER-positive & HER2-positive advanced breast cancer🧪 #BreastCancerAwarenessMonth plos.io/4iu26Xe
Dalpiciclib combined with pyrotinib and endocrine therapy in women with ER-positive, HER2-positive advanced breast cancer: A prospective, multicenter, single-arm, phase 2 trial
Jian Zhang, Yanchun Meng and colleagues assess the activity and safety of combining dalpiciclib with pyrotinib and endocrine therapy in patients receiving first- or second-line treatment for ER-positi...
plos.io
October 19, 2026 at 11:15 AM
In a single-arm phase 2 trial, Jian Zhang, Yanchun Meng &co assess activity & safety of combining dalpiciclib with pyrotinib & endocrine therapy in patients receiving first- or second-line treatment for ER-positive & HER2-positive advanced breast cancer🧪 #BreastCancerAwarenessMonth plos.io/4iu26Xe
🧬A novel HER2-directed antibody-drug conjugate delivered PFS benefit in HER2+ metastatic Breast Cancer
In HORIZON-Breast01, trastuzumab rezetecan reduced risk of progression/death by 78% vs pyrotinib + capecitabine.
▪️Erwei Song, MD | The Lancet Oncology
🔗 https://ow.ly/6wCY50ZyGzw
In HORIZON-Breast01, trastuzumab rezetecan reduced risk of progression/death by 78% vs pyrotinib + capecitabine.
▪️Erwei Song, MD | The Lancet Oncology
🔗 https://ow.ly/6wCY50ZyGzw
September 22, 2026 at 1:00 PM
🧬A novel HER2-directed antibody-drug conjugate delivered PFS benefit in HER2+ metastatic Breast Cancer
In HORIZON-Breast01, trastuzumab rezetecan reduced risk of progression/death by 78% vs pyrotinib + capecitabine.
▪️Erwei Song, MD | The Lancet Oncology
🔗 https://ow.ly/6wCY50ZyGzw
In HORIZON-Breast01, trastuzumab rezetecan reduced risk of progression/death by 78% vs pyrotinib + capecitabine.
▪️Erwei Song, MD | The Lancet Oncology
🔗 https://ow.ly/6wCY50ZyGzw
First-line pyrotinib plus apatinib in advanced non-small cell #LungCancer harboring HER2 mutations or amplification: a phase II trial. www.lungcancerjournal.info/article/S016...
First-line pyrotinib plus apatinib in advanced non-small cell lung cancer harboring HER2 mutations or amplification: a phase II trial
Human epidermal growth factor receptor 2 (HER2), belonging to the ERBB receptor tyrosine
kinase family, mediates downstream signaling activation through ligand-independent
homo- or heterodimerization ...
www.lungcancerjournal.info
August 28, 2026 at 9:30 AM
First-line pyrotinib plus apatinib in advanced non-small cell #LungCancer harboring HER2 mutations or amplification: a phase II trial. www.lungcancerjournal.info/article/S016...
❓ Can a >30-month median progression-free survival redefine second-line HER2-positive metastatic breast cancer treatment?
www.thelancet.com/journals/lan...
📰 Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01)
www.thelancet.com/journals/lan...
📰 Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01)
August 5, 2026 at 9:45 AM
❓ Can a >30-month median progression-free survival redefine second-line HER2-positive metastatic breast cancer treatment?
www.thelancet.com/journals/lan...
📰 Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01)
www.thelancet.com/journals/lan...
📰 Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01)
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
July 3, 2026 at 12:51 PM
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
Integrative analysis of scRNA-seq, spatial transcriptomics, and machine learning constructs a prognostic model for Pyrotinib resistance in breast cancer #SingleCell 🧪🧬🖥️
https://www.researchsquare.com/article/rs-9376197/latest
https://www.researchsquare.com/article/rs-9376197/latest
April 16, 2026 at 4:00 PM
Integrative analysis of scRNA-seq, spatial transcriptomics, and machine learning constructs a prognostic model for Pyrotinib resistance in breast cancer #SingleCell 🧪🧬🖥️
https://www.researchsquare.com/article/rs-9376197/latest
https://www.researchsquare.com/article/rs-9376197/latest
An LC-MS/MS method for simultaneous quantification of pyrotinib, docetaxel and paclitaxel in human plasma and its application to therapeutic drug monitoring #JChromB www.sciencedirect.com/science/arti...
An LC-MS/MS method for simultaneous quantification of pyrotinib, docetaxel and paclitaxel in human plasma and its application to therapeutic drug monitoring
Pyrotinib which is a novel irreversible tyrosine kinase inhibitor plus docetaxel or paclitaxel is effective for patients with Her2 positive early or a…
www.sciencedirect.com
October 30, 2025 at 11:39 AM
An LC-MS/MS method for simultaneous quantification of pyrotinib, docetaxel and paclitaxel in human plasma and its application to therapeutic drug monitoring #JChromB www.sciencedirect.com/science/arti...
[5/7] pyrotinib, covering the entire treatment cycle from early adjuvant to late first-line and post-line treatment, consolidating the company's leading position in the field of breast tumors. The company's revenue from innovative drugs has grown rapidly, and "borrowing ships to go
July 8, 2026 at 7:45 AM
[5/7] pyrotinib, covering the entire treatment cycle from early adjuvant to late first-line and post-line treatment, consolidating the company's leading position in the field of breast tumors. The company's revenue from innovative drugs has grown rapidly, and "borrowing ships to go
[5/7] pyrotinib, covering the entire treatment cycle from early adjuvant to late first-line and post-line treatment, consolidating the company's leading position in the field of breast tumors. The company's revenue from innovative drugs has grown rapidly, and "borrowing ships to go
July 8, 2026 at 7:44 AM
[5/7] pyrotinib, covering the entire treatment cycle from early adjuvant to late first-line and post-line treatment, consolidating the company's leading position in the field of breast tumors. The company's revenue from innovative drugs has grown rapidly, and "borrowing ships to go
#Article in @MedComm_MC
Triple #HER2 Blockade With #Trastuzumab, #Pertuzumab, and #Pyrotinib Versus Dual HER2 Blockade in the #Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Randomized, Phase II Study doi.org/10.1002/mco2...
#ClinicalTrial
Triple #HER2 Blockade With #Trastuzumab, #Pertuzumab, and #Pyrotinib Versus Dual HER2 Blockade in the #Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Randomized, Phase II Study doi.org/10.1002/mco2...
#ClinicalTrial
Triple HER2 Blockade With Trastuzumab, Pertuzumab, and Pyrotinib Versus Dual HER2 Blockade in the Neoadjuvant Treatment of HER2‐Positive Breast Cancer: A Randomized, Phase II Study
Triple HER2 blockade with trastuzumab, pertuzumab, and pyrotinib (TPPy) did not improve total pathological complete response (tpCR) rates or breast pathological complete response (bpCR) rates compare....
doi.org
January 23, 2026 at 3:47 AM
#Article in @MedComm_MC
Triple #HER2 Blockade With #Trastuzumab, #Pertuzumab, and #Pyrotinib Versus Dual HER2 Blockade in the #Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Randomized, Phase II Study doi.org/10.1002/mco2...
#ClinicalTrial
Triple #HER2 Blockade With #Trastuzumab, #Pertuzumab, and #Pyrotinib Versus Dual HER2 Blockade in the #Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Randomized, Phase II Study doi.org/10.1002/mco2...
#ClinicalTrial
Wrapping up with the #SABCS21 "Year in Review" on MBC, presented by Dr Peter Schmid. First up: HER2+ MBC. TDxd was the big story of 2020/early 2021 - it's moved to recommended 2nd line therapy and might even become 1st line. ADC SYD985 and TKI pyrotinib are ones to keep👀 too.
November 17, 2024 at 2:07 PM
Wrapping up with the #SABCS21 "Year in Review" on MBC, presented by Dr Peter Schmid. First up: HER2+ MBC. TDxd was the big story of 2020/early 2021 - it's moved to recommended 2nd line therapy and might even become 1st line. ADC SYD985 and TKI pyrotinib are ones to keep👀 too.
📘 Evidence for post-progression strategies in HER2+ metastatic #BreastCancer with brain metastases remains limited. This multicenter real-world study adds insight into pyrotinib treatment beyond progression and rechallenge:
buff.ly/0sbfEcd
#ClinicalResearch
buff.ly/0sbfEcd
#ClinicalResearch
July 3, 2026 at 7:02 AM
📘 Evidence for post-progression strategies in HER2+ metastatic #BreastCancer with brain metastases remains limited. This multicenter real-world study adds insight into pyrotinib treatment beyond progression and rechallenge:
buff.ly/0sbfEcd
#ClinicalResearch
buff.ly/0sbfEcd
#ClinicalResearch
Pyrotinib plus trastuzumab and docetaxel outperformed trastuzumab and docetaxel alone as an initial treatment for HER2-positive metastatic #breastcancer. Published in @bmj.com and @cancertherapyadv.bsky.social.
https://bit.ly/47TBedD
#bcsm
https://bit.ly/47TBedD
#bcsm
PHILA: Pyrotinib-Based Dual Anti-HER2 Regimen Extended Survival in Metastatic Breast Cancer - Oncology Nurse Advisor
Investigators delivered updated results from the phase 3 PHILA trial evaluating the pyrotinib or placebo plus trastuzumab and docetaxel in patients with untreated HER2+metastatic breast cancer.
bit.ly
March 29, 2026 at 7:17 PM
Pyrotinib plus trastuzumab and docetaxel outperformed trastuzumab and docetaxel alone as an initial treatment for HER2-positive metastatic #breastcancer. Published in @bmj.com and @cancertherapyadv.bsky.social.
https://bit.ly/47TBedD
#bcsm
https://bit.ly/47TBedD
#bcsm
At #SABCS24 GS1
Final survival results of PHILA, a chinese “Cleopatra” with pyrotinib 🇨🇳
Pyrotinib, trastuzumab, docetaxel as 1️⃣st line in HER2+ metastatic breast cancer ⬆️ PFS(HR 0.44) and ⬆️OS (HR 0.64) vs. Placebo, trastu, docetaxel
⬆️Diarrhea w/pyrotinib
@oncoalert.bsky.social
Final survival results of PHILA, a chinese “Cleopatra” with pyrotinib 🇨🇳
Pyrotinib, trastuzumab, docetaxel as 1️⃣st line in HER2+ metastatic breast cancer ⬆️ PFS(HR 0.44) and ⬆️OS (HR 0.64) vs. Placebo, trastu, docetaxel
⬆️Diarrhea w/pyrotinib
@oncoalert.bsky.social
December 11, 2024 at 4:05 PM
At #SABCS24 GS1
Final survival results of PHILA, a chinese “Cleopatra” with pyrotinib 🇨🇳
Pyrotinib, trastuzumab, docetaxel as 1️⃣st line in HER2+ metastatic breast cancer ⬆️ PFS(HR 0.44) and ⬆️OS (HR 0.64) vs. Placebo, trastu, docetaxel
⬆️Diarrhea w/pyrotinib
@oncoalert.bsky.social
Final survival results of PHILA, a chinese “Cleopatra” with pyrotinib 🇨🇳
Pyrotinib, trastuzumab, docetaxel as 1️⃣st line in HER2+ metastatic breast cancer ⬆️ PFS(HR 0.44) and ⬆️OS (HR 0.64) vs. Placebo, trastu, docetaxel
⬆️Diarrhea w/pyrotinib
@oncoalert.bsky.social
Dynamic characterization of circulating tumor DNA in HER2-altered advanced non-small cell lung cancer treated with pyrotinib and apatinib: Exploratory biomarker analysis from PATHER2 study www.lungcancerjournal.info/article/S01...
December 26, 2024 at 3:15 PM
Dynamic characterization of circulating tumor DNA in HER2-altered advanced non-small cell lung cancer treated with pyrotinib and apatinib: Exploratory biomarker analysis from PATHER2 study www.lungcancerjournal.info/article/S01...
📍 Zongertinib outperforms pan-HER TKIs like pyrotinib (19–30% response, high diarrhea rates) and poziotinib (27–28% response, severe rash). Plus, no drug-related interstitial lung disease reported!
#Onco404 #Cancer #Kanser #MedSky #OncSky #LungCancer #AkciğerKanseri
#Onco404 #Cancer #Kanser #MedSky #OncSky #LungCancer #AkciğerKanseri
May 19, 2025 at 5:41 PM
📍 Zongertinib outperforms pan-HER TKIs like pyrotinib (19–30% response, high diarrhea rates) and poziotinib (27–28% response, severe rash). Plus, no drug-related interstitial lung disease reported!
#Onco404 #Cancer #Kanser #MedSky #OncSky #LungCancer #AkciğerKanseri
#Onco404 #Cancer #Kanser #MedSky #OncSky #LungCancer #AkciğerKanseri
Feed: "2 Minute Medicine"
By: Siwen Liu on Monday, March 23, 2026
By: Siwen Liu on Monday, March 23, 2026
Pyrotinib provides survival benefit in human epidermal growth factor receptor 2-positive metastatic breast cancer when combined with trastuzumab and docetaxel
1. Pyrotinib combined with trastuzumab and docetaxel prolonged progression-free survival compared to placebo combined with trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer. Evidence Rating Level: 1 (Excellent) Study Rundown: The human epidermal growth factor receptor 2 (HER2)-positive subtype of breast cancer involves rapid disease progression
www.2minutemedicine.com
March 24, 2026 at 6:48 AM
Feed: "2 Minute Medicine"
By: Siwen Liu on Monday, March 23, 2026
By: Siwen Liu on Monday, March 23, 2026
Improvement in PFS and OS with combination of pyrotinib + Herceptin + docetaxel @sabcs.bsky.social @oncoalert.bsky.social
December 11, 2024 at 4:03 PM
Improvement in PFS and OS with combination of pyrotinib + Herceptin + docetaxel @sabcs.bsky.social @oncoalert.bsky.social
📌Pyrotinib or Placebo in Combination with Trastuzumab and Docetaxel for Untreated HER2-Positive Metastatic Breast Cancer (mBC): Prespecified Final Analysis of Progression-Free Survival (PFS) of the Phase 3 PHILA Trial by Binghe Xu
#SABCS24 #GeneralSession1 #day2 @oncoalert.bsky.social #OncoAlertAF
#SABCS24 #GeneralSession1 #day2 @oncoalert.bsky.social #OncoAlertAF
December 11, 2024 at 4:01 PM
📌Pyrotinib or Placebo in Combination with Trastuzumab and Docetaxel for Untreated HER2-Positive Metastatic Breast Cancer (mBC): Prespecified Final Analysis of Progression-Free Survival (PFS) of the Phase 3 PHILA Trial by Binghe Xu
#SABCS24 #GeneralSession1 #day2 @oncoalert.bsky.social #OncoAlertAF
#SABCS24 #GeneralSession1 #day2 @oncoalert.bsky.social #OncoAlertAF
Ther Adv Med Oncol: Real‑world pyrotinib beyond progression vs rechallenge in HER2+ mBC (incl. brain mets): PFS2 ~7.2 vs 6.3 mo (NS); OS 31.6 vs 21.0 mo (trend). CNS subgroup also benefited. Read: 【🔗https://buff.ly/xsK4lFw 】 #BreastCancer #HER2 #BrainMets #Oncology
March 7, 2026 at 8:15 AM
Ther Adv Med Oncol: Real‑world pyrotinib beyond progression vs rechallenge in HER2+ mBC (incl. brain mets): PFS2 ~7.2 vs 6.3 mo (NS); OS 31.6 vs 21.0 mo (trend). CNS subgroup also benefited. Read: 【🔗https://buff.ly/xsK4lFw 】 #BreastCancer #HER2 #BrainMets #Oncology
ARX788 Combo Outperforms Standard HER2+ Breast Cancer Therapy
In a groundbreaking phase 2b clinical trial published in Nature Communications, researchers have explored an innovative therapeutic approach for HER2-positive breast cancer, comparing the efficacy of a novel antibody-drug conjugate,…
In a groundbreaking phase 2b clinical trial published in Nature Communications, researchers have explored an innovative therapeutic approach for HER2-positive breast cancer, comparing the efficacy of a novel antibody-drug conjugate,…
ARX788 Combo Outperforms Standard HER2+ Breast Cancer Therapy
In a groundbreaking phase 2b clinical trial published in Nature Communications, researchers have explored an innovative therapeutic approach for HER2-positive breast cancer, comparing the efficacy of a novel antibody-drug conjugate, ARX788, combined with the irreversible tyrosine kinase inhibitor pyrotinib, against the current standard neoadjuvant regimen consisting of trastuzumab, pertuzumab, docetaxel, and carboplatin. The trial’s results not only promise a paradigm shift in targeted treatment strategies but also underscore the potential for more effective and less toxic alternatives for patients battling this aggressive subtype of breast cancer.
scienmag.com
July 1, 2025 at 4:13 PM
ARX788 Combo Outperforms Standard HER2+ Breast Cancer Therapy
In a groundbreaking phase 2b clinical trial published in Nature Communications, researchers have explored an innovative therapeutic approach for HER2-positive breast cancer, comparing the efficacy of a novel antibody-drug conjugate,…
In a groundbreaking phase 2b clinical trial published in Nature Communications, researchers have explored an innovative therapeutic approach for HER2-positive breast cancer, comparing the efficacy of a novel antibody-drug conjugate,…
Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A multicenter phase II trial https://www.medrxiv.org/content/10.1101/2024.09.05.24313095v1
Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A multicenter phase II trial https://www.medrxiv.org/content/10.1101/2024.09.05.24313095v1
Background Approximately one-third of patients with HER2-positive breast cancer experienced recurren
www.medrxiv.org
September 5, 2024 at 6:29 PM
Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A multicenter phase II trial https://www.medrxiv.org/content/10.1101/2024.09.05.24313095v1